A Blood Test for Colon Cancer

A blood test for colon cancer performed well in a study published Wednesday, offering a new kind of screening for a leading cause of cancer deaths.

The test looks for DNA fragments shed by tumor cells and precancerous growths. It’s already for sale in the U.S. for $895, but has not been approved by the Food and Drug Administration and most insurers do not cover it. The maker of the test, Guardant Health, anticipates an FDA decision this year.

In the study, the test caught 83% of the cancers but very few of the precancerous growths found by colonoscopy, the gold standard for colon cancer screening. Besides spotting tumors, colonoscopies can prevent the disease by removing precancerous growths called polyps.

But some people avoid the exam because of the hassle of getting time off work or the day-ahead preparation that involves drinking a strong laxative to empty the bowels.

A convenient alternative is an annual stool test, where people send a stool sample to a lab for analysis.

Read More: The Unique Hell of Getting Cancer as a Young Adult

“The best test is the one someone will actually complete,” said Dr. Douglas Corley, chief research officer for Kaiser Permanente, Northern California, who was not involved in the study. “Giving people a choice increases the number of people who will get screened.”

In the U.S., screening is recommended for healthy adults ages 45 to 75 at average risk for colon cancer. Frequency depends on the test: a routine colonoscopy is every 10 years. Screening is inching up but falls well short of the 80% of age-eligible adults goal set by the American Cancer Society and other groups.

Guardant recommends testing with its blood test called Shield every three years. Like a stool test, the blood test requires a follow-up colonoscopy if there’s an abnormal result, which could lead to more out-of-pocket costs.

The study, sponsored by Guardant and published in the New England Journal of Medicine, involved 7,861 people in the U.S. who had both a colonoscopy and a blood test.

While the blood test caught 83% of the cancers found by colonoscopy, it missed 17%. That’s on par with stool-based tests.

Read More: 7 Myths About Kidney Cancer

There were also false alarms: For 10% of the people where the colonoscopy found nothing, the blood test falsely indicated they might have colon cancerคำพูดจาก สล็อตเว็บตรง. That means a sizeable number of people would face the anxiety of follow-up colonoscopies.

The blood test is tuned to pick up the signature of colon cancer but more research is needed to determine if it might pick up other cancers as well and give misleading results, Corley said.

Colorectal cancer is the second leading cause of cancer deaths in the United States and the third worldwide. In the U.S., more than 153,000 new cases and 53,000 deaths from the disease are expected this year.

More screening should result in fewer cancer deaths, said study co-author Dr. William Grady of the Fred Hutchinson Cancer Center in Seattle and a paid member of Guardant’s scientific advisory board.

In a separate study published Wednesday in the same journal, an updated version of the Cologuard stool test, which also looks for DNA fragments, seemed to improve its performance on false alarms, possibly leading to fewer follow-up colonoscopies. That study, involving more than 20,000 people, was sponsored by Exact Sciences, maker of the test.

“The more options we have for our patients, the better,” said Drคำพูดจาก สล็อตเว็บตรง. Nabil Mansour of Baylor College of Medicine, who was not involved in either study. He’ll continue to recommend a colonoscopy for his patients but “I’m excited there will be a pretty good blood test option available.”

Related Posts

20 Newsletters Every Marketer Needs To Stay Ahead Of The Curve

Electronic marketing and advertising companies Enjoy a huge position in encouraging personal models and businesses make their mark on the internet. With no aid of digital advertising and…

Building Blocks of Health- Discovering the Best Supplements for Every Age

While supplements can easily provide notable perks, they might likewise lug threats and also adverse effects or even utilized accurately. Higher dosages of particular vitamins as well as…

Brightstar Capital Partners to Acquire AGS for $1.1 Billion

PlayAGS Incorporated, listed on the New York Stock Exchange under the “AGS” ticker, a prominent gaming supplier known for its high-performing slot, table, and interactive products, has announced…

Climate Gets Its Day in Court

If you’re like most Americans, the name Kelsey Juliana might not mean a lot to you. But if you’re an attorney or other official with the Environmental Protection…